Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12145152
Jiang G, et al. (2002) Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes 51, 2412-9 12145152
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (rat)
Modsite: KDGATMKtFCGTPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Comments:  Lean, obese Zucker rats
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rosiglitazone no change compared to control
insulin rosiglitazone increase fat-obese and lean rats
rosiglitazone no change compared to control
nTZD no change compared to control
insulin, rosiglitazone increase
insulin, nTZD increase
rosiglitazone no change compared to control
insulin rosiglitazone increase day 1 IP Akt1
rosiglitazone no change compared to control
insulin rosiglitazone increase day 2 IP Akt2
rosiglitazone increase Day 1 IP Akt1
insulin rosiglitazone increase
rosiglitazone no change compared to control day 2 IP Akt2
insulin rosiglitazone no change compared to control
BRL37344 no change compared to control 7 day IP Akt1
insulin BRL37344 increase
BRL37344, nTZD no change compared to control 7 day IP Akt 1
BRL37344 no change compared to control day 7 IP AKT2
insulin BRL37344 no change compared to control
nTZD augment treatment-induced decrease day 7 IP AKt2
insulin no change compared to control
insulin increase
rosiglitazone no change compared to control
rosiglitazone insulin augment treatment-induced increase 3T3-L1 adipocytes
no change compared to control non TZD
insulin increase
insulin increase + Non TZD 3T3 L1 adipocytes
insulin increase
rosiglitazone no change compared to control
rosiglitazone insulin no effect upon treatment-induced increase Primary rat hepatocytes

S473-p - Akt1 (rat)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Comments:  Lean, obese Zucker rats
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase lean rat fat
insulin no change compared to control obese rat fat
rosiglitazone no change compared to control obese rat fat
insulin rosiglitazone increase

S21-p - GSK3A (rat)
Modsite: SGRARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Comments:  Lean, obese Zucker rats
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin no change compared to control obese rat fat
rosiglitazone no change compared to control obese rat day1
rosiglitazone insulin increase day2

S9-p - GSK3B (rat)
Modsite: SGRPRTTsFAESCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Comments:  Lean, obese Zucker rats
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin no change compared to control obese rat fat
rosiglitazone no change compared to control obese rat day1
rosiglitazone insulin increase day2